Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase

RIP1 has a role as an essential adaptor for signaling induced by a number of innate immune receptors including TNFR1 and other death receptors, TLR3 and TLR4. Studying the role of RIP1 in these pathways has revealed very distinct functions for RIP1 as a scaffolding protein and as a kinase. Although the scaffolding function of RIP1 is essential for rescuing the activation of cell death pathways under homeostatic conditions, the kinase activity of RIP1 is emerging as a driver of inflammation and tissue damage in a variety of disease settings, most notably involving the proinflammatory cytokine TNF. The pathogenic effects of RIP1 kinase activity have been attributed to its role in regulating an inflammatory form of necrotic cell death termed necroptosis. However, data are emerging to suggest that RIP1 kinase activity also contribute to the role of RIP1 kinase activity in driving inflammation.

Interest in the role that RIP1 kinase activity has in driving disease pathogenesis was sparked by the identification of the small-molecule RIP1 kinase inhibitor Necrostatin-1 (Nec-1). Nec-1 has been a transformational tool for exploring the function of RIP1 kinase activity; however, its utility is somewhat limited by moderate potency, off-target activity against indoleamine-2,3-dioxygenase (IDO), and poor pharmacokinetic properties. These limitations of Nec-1 have driven an effort to identify next-generation tools to study RIP1 function, and have led to the identification of 7-Cl-O-Nec-1 (Nec-1s), which has improved pharmacokinetic properties and lacks IDO inhibitory activity. Here we describe the characterization of GSK'963, a chiral small-molecule inhibitor of RIP1 kinase that is chemically distinct from both Nec-1 and Nec-1s. GSK'963 is significantly more potent than Nec-1 in both biochemical and cellular assays, inhibiting RIP1-dependent cell death with an IC50 of between 1 and 4 nM in human and murine cells. GSK'963 is >10 000-fold selective for RIP1 over 339 other kinases, lacks measurable activity against IDO and has an inactive enantiomer, GSK'962, which can be used to confirm on-target effects. The increased in vitro potency of GSK'963 also translates in vivo, where GSK'963 provides much greater protection from hypothermia at matched doses to Nec-1, in a model of TNF-induced sterile shock. Together, we believe GSK'963 represents a next-generation tool for examining the function of RIP1 in vitro and in vivo, and should help to clarify our current understanding of the role of RIP1 in contributing to disease pathogenesis.

Received 8 June 2015; accepted 10 June 2015; Edited by G Melino

1Pattern Recognition Receptor Discovery Performance Unit, Immuno-inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, PA, USA and 2Platform Technology and Science, GlaxoSmithKline, Collegeville, PA, USA.

Correspondence: J Bertin (john.j.bertin@gsk.com)

Current address: Host Defense Discovery Performance Unit, Infectious Disease Therapeutic Area, GlaxoSmithKline, Collegeville, PA 19426, USA.

Citation: Cell Death Discovery (2015) 1, 15009; doi:10.1038/cddiscovery.2015.9; published online 27 July 2015
sterile shock at a dose where Nec-1 shows no significant protection in the model. Taken together, we believe that GSK’963 represents an additional next-generation tool for exploring the role of RIP1 kinase-mediated biology.

RESULTS

GSK’963 is a potent and selective inhibitor of RIP1 kinase in biochemical assays
To identify novel inhibitors of RIP1 kinase, we screened the GSK compound collection, containing ~2 million compounds, for RIP1 inhibitors using an ADP-Glo enzymatic assay. Minor modification of a screening hit led to the identification of a racemic compound that was subsequently separated into active (GSK’963) and inactive (GSK’962) enantiomers (Figure 1a). GSK 963 was shown to be highly potent in the FP binding assay (IC50 = 29 nM), above the limit of detection for this assay. This contrasted markedly to Nec-1 and GSK’962 (Figure 1b), which displayed an ~70-fold drop off in potency (IC50 = 2 μM) or no activity in the assay, respectively, (Figure 1b). In accordance with the binding data, GSK’963 was also highly potent (IC50 = 8 nM with a 4 parameter curve fit or 0.8 nM with a tight binding fit) in blocking RIP1 kinase activity in comparison with Nec-1 (IC50 = 1 μM) and GSK’962, which was inactive (Figure 1c).

Generating selective inhibitors of kinases has historically been challenging and therefore, we assessed the selectivity of GSK’963 against a panel of 339 kinases in activity assays at 10 μM. GSK’963 was determined to be an ultra-selective RIP1 inhibitor, displaying <50% inhibition against all other kinases tested (Figure 1d; Supplementary Table I). Furthermore, GSK’963 was also inactive against indoleamine-2,3-dioxygenase (IDO) activity. This is in contrast to Nec-1, which has been reported to be a potent inhibitor of IDO.25 However, in our assays, Nec-1 also had no effect on IDO activity, whereas menadione, a natural inhibitor of IDO, inhibited enzyme activity with the expected potency (Figure 1e). Together these data demonstrate that GSK’963 is a highly potent and selective inhibitor of RIP1 kinase activity.

Figure 1. GSK’963A is a potent and selective inhibitor of RIP1 kinase. (a) Chemical structures of GSK’963A (active analog), GSK’962A (inactive analog) and Necrostatin-1. (b) Dose–response curves for GSK’963, GSK’962 and Nec-1 in the FP binding assay evaluating the affinity of compounds for RIP1 (ATP-binding pocket). Graphs represents n = 52 for Nec-1, n = 4 for GSK’962A and n = 7 for GSK’963A. Error bars indicate S.D. (c) Dose–response curves for GSK’963, GSK’962 and Nec-1 in ADP-Glo kinase assay measuring autophosphorylation of RIP1 kinase domain in vitro. Graph represents n = 20 for Nec-1, n = 2 for GSK’962A and n = 2 for GSK’963A. Error bars indicate S.D. (d) GSK’963 does not block the activity of any of the tested 339 human kinases at 10μM concentration, as evaluated at the Reaction Biology Corporation. Each dot represents an individual kinase with the color indicating the level of inhibition (red > 90%, yellow 70–90%, orange 50–70% and green < 50%) (e) Effect of GSK’963, GSK’962 and Nec-1 on indoleamine 2,3-dioxygenase (IDO) activity evaluated by an in vitro enzymatic assay. Menadione was used as a positive control for IDO inhibition. The results are representative of three independent experiments. = Nec-1, = GSK’962, = GSK’963 and = Menadione.
selective tool molecule with greater potency than Nec-1 in biochemical assays.

GSK'963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro

We next assessed the ability of GSK'963, GSK'962 and Nec-1 to block necroptosis in murine and human cell lines in vitro. To this end, mouse L929 and human U937 cells were stimulated with TNF +zVAD to induce necroptosis, and the ability of compounds to block cell death was evaluated overnight. GSK'963 efficiently blocked necroptosis in both murine and human cells with IC_{50} values of 1 nM and 4 nM, respectively, whereas the inactive analog GSK'962 was at least 1000-fold less potent in these assays (Figures 2a and b). Nec-1 was significantly less potent as compared with GSK'963, displaying IC_{50} values of 1 μM and 2 μM in L929 and U937 cells, respectively. The potency of the compounds was confirmed in primary mouse bone marrow-derived macrophages (BMDM). Cell viability was evaluated as in a. The graphs represent combined data from at least three independent experiments. Error bars represent S.D. (e) Cell viability and Caspase 3/7 activity were measured in BMDM treated with TNF and cycloheximide. Cell viability was measured using the CellTiter-Glo assay at 20 h, and Caspase 3/7 activity using the Caspase-Glo 3/7 assay at 3 h. GSK'963 and GSK'962 were used at 100 nM and Nec-1 was used at 10 μM. Similar data were generated in four independent experiments. Error bars represent S.D. between two experiments measured on the same plate. (f) Western blot analysis of IκB phosphorylation and degradation in BMDM stimulated with TNF. IκB phosphorylation was evaluated at 5 min and IκB degradation at 15 min. Tubulin was used as a loading control. GSK'963 and GSK'962 were used at 100 nM and Nec-1 was used at 10 μM. Data are representative of experiments from four different animals. ● = Nec-1, ■ = GSK'962, and ▲ = GSK'963. C, control; CHX, cycloheximide.
derived macrophages (BMDMs) and primary human neutrophils stimulated to induce necroptosis. In good agreement with the cell line data, the IC50 values were determined to be 3 nM for the primary mouse BMDMs and 0.9 nM for primary human neutrophils, with Nec-1 and GSK’963 being significantly less potent or inactive in the assays (Figures 2c and d).

Previous data have shown that TNF-induced activation of NF-κB, and TNF+cycloheximide (CHX)-stimulated apoptosis, occur independently of RIP1 kinase activity. We therefore used these assays to examine the cellular selectivity of GSK’963. Treatment with GSK’963 at 100 nM showed no measurable effects on TNF+c-CHX-stimulated apoptosis or TNF-induced NF-κB activation (Figures 2e and f). These results in conjunction with the wider pharmacodynamic modeling of both compounds based on the mouse pharmacokinetic profiles (Figure 3a; Supplementary Figure 1a) and compound potencies in TNF+zVAD-treated L929 cells (Figure 2a) indicated that at 2 mg/kg, GSK’963 would maintain blood concentrations above the concentration required for 90% inhibition of RIP1 activity for an extended period of time compared with Nec-1 (Figure 3b; Supplementary Figure 1b). To directly test the efficacy of GSK’963 in vivo, we made use an acute model of sterile shock. Administration of TNF+zVAD results in a lethal hypothermia that has previously been shown to be dependent on RIP1 kinase activity. Treatment of animals with 2 mg/kg of GSK’963 resulted in a complete protection from TNF+zVAD-induced temperature loss, with the 0.2 mg/kg dose also showing a significant response (Figure 3c). As expected, GSK’962 had no effect on the TNF+zVAD-induced shock, confirming that GSK’963 was acting selectively through RIP1 kinase inhibition (Figure 3d). Interestingly, Nec-1 had no effect in the model at 0.2 mg/kg, a dose that is commonly used to inhibit RIP1 in vivo in

GSK’963 is a potent inhibitor of a TNF+zVAD-mediated lethal shock.

We next assessed the pharmacokinetic profiles of GSK’963 and Nec-1 following intraperitoneal (i.p.) administration in vivo. Nec-1 demonstrated an ~10-fold higher exposure compared with GSK’963 at 10 mg/kg, although the apparent half-life of GSK’963 was greater than that for Nec-1 (Figure 3a; Supplementary Figure 1a). However, pharmacodynamic modeling of both compounds based on the mouse pharmacokinetic profiles (Figure 3a; Supplementary Figure 1a) and compound potencies in TNF+zVAD-treated L929 cells (Figure 2a) indicated that at 2 mg/kg, GSK’963 would maintain blood concentrations above the concentration required for 90% inhibition of RIP1 activity for an extended period of time compared with Nec-1 (Figure 3b; Supplementary Figure 1b). To directly test the efficacy of GSK’963 in vivo, we made use an acute model of sterile shock. Administration of TNF+zVAD results in a lethal hypothermia that has previously been shown to be dependent on RIP1 kinase activity. Treatment of animals with 2 mg/kg of GSK’963 resulted in a complete protection from TNF+zVAD-induced temperature loss, with the 0.2 mg/kg dose also showing a significant response (Figure 3c). As expected, GSK’962 had no effect on the TNF+zVAD-induced shock, confirming that GSK’963 was acting selectively through RIP1 kinase inhibition (Figure 3d). Interestingly, Nec-1 had no effect in the model at 0.2 mg/kg, a dose that is commonly used to inhibit RIP1 in vivo in

![Figure 3](image-url)

Figure 3. GSK’963A protects mice from TNF+zVAD-induced hypothermia. (a) Pharmacokinetic profile of GSK’963A dosed i.p. at 10 mg/kg in C57BL/6 mice. The data represent the combined results of the three independent animals. (b) Modeling of predicted % inhibition against RIP1 using the observed pharmacokinetic profile of GSK’963 in conjunction with the potency in inhibiting TNF+zVAD necroptosis in mouse L929 cells. ▲ = 2 mg/kg and ● = 0.2 mg/kg (c–e) The effect of GSK’963, GSK’962, and Nec-1 on temperature loss in the TNF+zVAD-induced shock model. C57BL/6 mice were pretreated i.p. with (c) GSK’963, (d) GSK’962A or (e) Nec-1 15 min prior to i.v. injection of TNF+zVAD. Temperature was monitored over the course of 3 h by rectal probe. The results are representative of three independent experiments, each containing seven animals per group. Error bars indicate the S.D. from the seven animals for each group. ○ = control mice, ● = TNF+zVAD-treated mice, ▲ = TNF+zVAD-treated mice dosed with GSK’963 at 0.2 mg/kg, ▼ = TNF+zVAD-treated mice dosed with GSK’963 at 2 mg/kg, ■ = TNF+zVAD-treated mice dosed with GSK’962 at 20 mg/kg, △ = TNF+zVAD with Nec-1 at 2 mg/kg and ▼ = TNF+zVAD with Nec-1 at 0.2 mg/kg.
the literature, and showed a minimal level of protection at a 10-fold higher dose (Figure 3e). Together these results demonstrate that compared with Nec-1, GSK’963 represents a better tool molecule to explore acute RIP1 kinase biology in vivo.

DISCUSSION
Over the last few years, RIP1 kinase-dependent necroptosis and signaling has emerged as a key driver of inflammation and disease pathology. In parallel with the data supporting an inflammatory role for RIP1 kinase activity, the complexities surrounding RIP1-dependent signaling pathways have become better appreciated. It is now clear that RIP1 has very distinct roles as a scaffolding protein and as a kinase, with this most readily seen in the very distinct phenotypes of RIP1-deficient and RIP1 kinase-dead knock-in mice. In addition, it was initially suggested that the sole role of RIP1 kinase activity was to regulate RIP3-dependent necroptosis, and hence RIP3-deficient mice were assumed to be a surrogate of the absence of RIP1 kinase activity. However, recent data suggest that RIP3-deficient and RIP1 kinase-dead knock-in mice can have different phenotypes in inflammatory models, and that RIP1 kinase activity can also be involved in regulating apoptosis and the production of inflammatory mediators. Although these genetic systems are powerful, small-molecule inhibitors are extremely important in understanding the biology of RIP1 in situations where genetic models cannot be used, particularly in human cell systems.

The RIP1 inhibitor Nec-1 has been widely used in vitro cellular systems, and has led to many important insights into RIP1 function. However, the moderate potency of Nec-1 has often led to it being utilized at concentrations of tens of micromolar. At these concentrations, it becomes hard to confidently discern whether the biological effects of Nec-1 are being mediated through inhibition of RIP1, or through off-target activities such as inhibition of IDO. Although optimized necrostatins, such as Nec-1s, have been generated, which are devoid of IDO activity, their moderate potency still raises questions about on-target versus off-target activity. In this regard, we believe that GSK’963 represents a significant advance for studying RIP1 function in vitro settings, due to its low nanomolar activity in human- and murine cell-based assays, its exquisite kinase activity, and the ability to use the inactive enantiomer GSK 962 to control for off-target activities.

The increased potency of GSK’963 relative to Nec-1 in vitro also translated into increased efficacy in the TNF-zVAD-induced model of sterile shock. At a dose of 2 mg/kg, GSK’963 was able to completely inhibit temperature loss in response to TNF-zVAD, recapitulating the phenotype of the recently described RIP1 kinase-dead knock-in mice. The level of inhibition of temperature loss in this acute model at different doses of GSK’963 was in line with the predictions of efficacy based on modeling of the pharmacokinetic profile and in vitro potency of GSK’963 (Figures 3b and c). Extending this modeling out over 24 h revealed that multiple, large doses of GSK’963 would be required to produce significant levels of RIP1 inhibition, making it unsuitable as a tool to study RIP1 function in chronic models of inflammation and disease (data not shown). We are currently working to identify analogs of GSK’963 with improved metabolic stability and pharmacokinetic properties that may represent superior tools for studying RIP1 function in vivo.

In our hands, administration of Nec-1 at doses commonly used in the literature to study RIP1 function had minimal effect in the RIP1-dependent TNF-zVAD model of sterile shock. This lack of efficacy was in agreement with the modeled RIP1 inhibition for Nec-1 (Supplementary Figure 1b) and reflects the moderate potency, and metabolic instability of Nec-1 and the corresponding short in vivo half-life for the compound. It is also possible that modifications to the vehicle used to dose Nec-1 may modestly increase the levels of compound around the time of dosing, administration of Nec-1 at doses used in the literature will only be able to generate moderate, short-lived inhibition of RIP1 in chronic in vivo models. In this regard, many of the models of inflammation and disease, where RIP1 inhibition by Nec-1 has shown benefit, should be reevaluated when further optimized RIP1 inhibitors are available, in order to define the effects of more complete inhibition of RIP1 kinase activity. Furthermore, it will be informative for the field if future publications of in vivo studies using Nec-1 contain measurements of circulating compound levels in order to better understand the magnitude of RIP1 inhibition achieved.

Taken together, we have identified a novel, highly potent and selective inhibitor of RIP1 kinase activity. We believe that GSK’963 represents a next-generation tool inhibitor for investigating RIP1 biology in vitro, offering a significant benefit over the commercially available necrostatins.

MATERIALS AND METHODS
Mice
C57BL/6 mice were purchased from Taconic (Hudson, NY, USA) and housed under specific pathogen-free conditions. All animal procedures were conducted in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility at GlaxoSmithKline in accordance with the GlaxoSmithKline Policy on the Care, Welfare, and Treatment of Laboratory Animals and were reviewed and approved by the Institutional Animal Care and Use Committee at GlaxoSmithKline.

Fluorescent polarization (FP) binding assay
A FP-based binding assay was developed to quantitate interaction of novel test compounds at the ATP-binding pocket of RIP1, by competition with a fluorescently labeled ATP-competitive ligand, as previously described.

In brief, GST-RipK1 (1–375) was purified and used at a final assay concentration of 10 nM. A fluorescent-labeled ligand (14-(2-[3-(2-[4-(cyanoamethyl)phenyl]amino)-6-[5-cyclopropyl-1H-pyrazol-3-yl]amino]-4-pyrimidyl)amino) propyl]amino)-2-oxoethyl)-16,16,18-tetramethyl-6,7,7a,8a,9,10,16,18-octahydrobenzo[2′,3′:5′,6′]indolizinol[8′,7′:5′,6′][pyrano[3′:2′:3]pyrano[1,2:a]indol-5-ium-2-sulfonate was used at a final assay concentration of 5 nM. Samples were read on an Analyst multimode reader ( Molecular Devices, Sunnyvale, CA, USA). Test compound inhibition was expressed as percent (%) inhibition of internal assay controls.

ADP-Glo kinase assay
Compound potency against RIP1 kinase activity was determined using an ADP-Glo luminescence assay, which measures the conversion of ATP to ADP, as previously described. In brief, the primary reaction consisted of 10 nM GST-RipK1 (1–375) and 50 μM ATP in 50 mM HEPES pH 7.5, 5 mM NaCl, 30 mM MgCl2, 1 mM DTT, 0.5 mg/ml BSA, and 0.02% CHAPS. Five microliter of enzyme and 5 μl of ATP were added to the plate at twice the final assay concentration and incubated at room temperature for 4 h. The luminescence was measured on a plate reader. Test compound inhibition was expressed as percent inhibition of internal assay controls.

Kinase selectivity
GSK’963 was tested against 339 kinases using a P33-radioabeled assay at Reaction Corp Biology (http://www.reactionbiology.com). The compound was tested at a single dose in duplicate at 10 μM. Reactions were carried out at 10 μM ATP. Data are reported as % enzyme activity (relative to DMSO controls). The full data set is shown in the Supplementary Table I.

IDO enzymatic assay
IDO activity was determined as described by Takahashi et al, using recombinant human IDO purchased from R&D Systems (Minneapolis, MN, USA). The yellow pigment derived from kynurenine was measured at 490 nm using the Spectramax microplate reader (Molecular Devices).
Cell culture
Mouse fibrosarcoma L929 cells (ATCC® CCL-1) and human monocytic U937 cells (ATCC® CRL-15932) were cultured in RPMI media supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin and 100 U/mL streptomycin. BMDM were prepared from C57BL/6 mice by differentiation with 10 ng/ml M-CSF (R&D Systems) for 7 days and cultured in DMEM medium supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin, 100 μg/mL streptomycin and 0.25 μg/mL amphotericin. Primary human neutrophils were isolated from human blood following the standard method comprised of sequential sedimentation in dextran, density centrifugation in Ficol-Hypaque and lysis of contaminating red blood cells.

Cell-based assays
Necrotic cell death was induced in BMDM, L929 and U937 cells with TNF in the presence of caspase inhibitor ZVAD-FMK or QVD-OpH (BMDM: 50 ng/mL TNF+50 μM ZVAD; L929: 100 ng/mL TNF+50 μM QVD; U937: 100 ng/mL TNF+12.5 μM QVD). To evaluate the effect of RIP1 inhibitors, cells were pretreated with compound (dose-response) for 30 min. Induced cell death was evaluated 19–21 h later by measuring cellular ATP levels using CellTiter-Glo Luminescent Cell Viability assay (Promega, Fitchburg, WI, USA). To induce necroptosis in neutrophils, freshly isolated human neutrophils were stimulated with TNF (10 ng/mL), QVD-OpH (50 μM) and SMAC mimetic (100 nM). Induced cell death was evaluated as above.

Caspase 3/7 assay
To induce apoptosis, BMDM pretreated with GSK’963 (100 nM), GSK’962 (100 nM) or Nec-1 (10 μM) for 30 min were stimulated with TNF (50 ng/mL, R&D Systems) and CHX (12 μg/mL, Sigma, St. Louis, MO, USA). Caspase 3/7 activity was measured at 6 h using the Caspase-Glo 3/7 assay (Promega).

Western blotting
For immunoblot analysis, BMDM pretreated with GSK’963 (100 nM), GSK’962 (100 nM) or Nec-1 (10 μM) for 30 min, were stimulated with 50 ng/mL TNF for 5 and 15 min. Lysates prepared in 1× Cell Lysis Buffer (Cell Signaling, Danvers, MA, USA) containing protease and phosphatase inhibitors were separated on 4% SDS-PAGE and blotted onto nitrocellulose membrane (Invitrogen, Waltham, MA, USA). Blots were probed for IKBα (9242, Cell Signaling), phospho-IκBα (9242, Cell Signaling), phospho-p38 (9215, Cell Signaling), phospho-ERK1/2 (4370, Cell Signaling) and tubulin as a loading control.

Pharmacokinetic experiments
Briefly, pharmacokinetic studies were conducted using n=3 animals per group for each compound. Animals received either GSK’963 or GSK’962 (100 nM) i.p. as an i.p. injection prepared as aqueous solutions in 6% 11-b-hydroxypropyl cyclodextrin and contained 5% DMSO. Blood samples were obtained at various time points following intraperitoneal injection and diluted 1:1 with water prior to storage at −80 °C. Prior to bioanalysis, samples were thawed and each sample was isolated into 30% acetonitrile for analysis.

To induce apoptosis, BMDM pretreated with GSK’963 (100 nM), GSK’962 (100 nM) or Nec-1 (10 μM) for 30 min, were stimulated with 50 ng/mL TNF for 5 and 15 min. Lysates prepared in 1× Cell Lysis Buffer (Cell Signaling, Danvers, MA, USA) containing protease and phosphatase inhibitors were separated on 4–12% SDS-PAGE and blotted onto nitrocellulose membrane (Invitrogen, Waltham, MA, USA). Blots were probed for IKBα (9242, Cell Signaling), phospho-IKBα (9242, Cell Signaling) and tubulin as a loading control.

REFERENCES
1 Gentile IE, Wong WW, Evans JM, Bankovacki A, Cook WD, Khan NR et al. In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-kappaB and activation of caspase-8. J Biol Chem 2011; 286: 13282–13291.
2 Meylan E, Burns K, Hofmann K, Blanchetue V, Martinon F, Kellner M et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappaB activation. Nat Immunol 2004; 5: 503–507.
3 Cusson-Hermanne N, Khurana S, Lee TH, Fitzgerald KA, Kellher MA. Rip1 mediates the TNF-dependent toll-like receptor 3- and 4-induced NF-kappaB activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem 2005; 280: 36560–36566.
4 Lee TH, Shank J, Cusson N, Kellher MA. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem 2004; 279: 33185–33191.
5 Berger SB, Kasparcova V, Hoffman S, Swift D, Dare L, Schaeffer M et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol 2014; 192: 5476–5480.
6 Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014; 343: 1357–1360.
7 Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van TM et al. Cutting edge: RIP1 kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol 2014; 193: 1539–1543.
8 Takahashi N, Vereecke L, Bertrand MMM, Duprez L, Berger SB, Divert T et al. RIPK1 prevents intestinal homeostasis by protecting the epithelium against apoptosis. Nature 2014; 513: 95–99.
9 Danappel M, Vlantis K, Kuman S, Polykratis A, Kim C, Wachsmuth L et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014; 513: 90–94.
10 Bonnet MC, Preukschatz D, Welz PS, van LG, Ermolaeva MA, Bloch W et al. The adaptor protein FADD protects epithelial keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity 2011; 35: 572–582.
11 Gunther C, Martini E, Wittkopf N, Amann K, Wegmann B, Neumann H. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477: 335–339.
12 Degterev A, Hitomi J, Germseid M, Ch’en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatin. Nat Chem Biol 2008; 4: 313–321.
13 Morioqa S, Broglie P, Omori E, Ikeda Y, Takaesu G, Matsumoto K et al. TAK1 kinase switches cell fate from apoptosis to necrosis following TNF stimulation. J Cell Biol 2014; 204: 607–623.
14 Christofferson DE, Li Y, Hitomi J, Zhou H, Upperman C, Zhu H et al. A novel role for RIP1 kinase in mediating TNF[alpha] production. Cell Death Dis 2012; 3: e320.
15 Degterev A, Huang Z, Boyle M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112–119.
16 Nagar M, Suebsuwong C, Ray SS, Thapa RJ, Maki JL, Nagusa S et al. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep 2015; 10: 1850–1860.
17 Fauster A, Rebsamen M, Huber KV, Bignenzahn JW, Stukalov A, Lardeau CH et al. ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis 2013; 4: e1767.
18 Harris PA, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti CA, Cox JA et al. Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis. ACS Med Chem Lett 2013; 4: 1238–1243.
19 Cho Y, McQuade T, Zhang H, Zhang J, Chan FK. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS One 2011; 6: e23209.
20 You Z, Savitz SI, Yang J, Degterev A, Yuan J, Cuny GD et al. Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab 2008; 28: 1564–1573.
21 Zhou Y, Dai W, Lin C, Wang F, He L, Shen M et al. Protective effects of necrostatin-1 against concanavalin A-induced acute hepatic injury in mice. Mediators Inflamm 2013; 2013: 706156.
22 Muller AJ, DuHadaway JB, Donover PS, Sutanto-ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer.
suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312–319.

23 Teng X, Degterev A, Jagtap P, Xing X, Choi S, Denu J R \textit{et al}. Structure–activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett 2005; 15: 5039–5044.

24 Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ 2013; 20: 366.

25 Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB \textit{et al}. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.

26 Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297–303.

27 He S, Wang L, Miao L, Wang T, Du F, Zhao L \textit{et al}. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100–1111.

28 Weng D, Marty-Roix R, Ganesan S, Proulx MK, Vladimir Gl, Kaiser WJ \textit{et al}. Caspase-8 and RIP kinases regulate bacteria-induced innate immune responses and cell death. Proc Natl Acad Sci USA 2014; 111: 7391–7396.